ONC
BeiGene, Ltd.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$35.86B
P/E Ratio
126.39
EPS
$2.47
Beta
0.54
52W High
$385.22
52W Low
$218.31
50-Day MA
$320.00
200-Day MA
$315.39
Dividend Yield
—
Profit Margin
5.37%
Forward P/E
53.76
PEG Ratio
—
About BeiGene, Ltd.
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Fundamentals
| Revenue (TTM) | $5.34B |
| Gross Profit (TTM) | $4.67B |
| EBITDA | $578.82M |
| Operating Margin | 12.30% |
| Return on Equity | 7.46% |
| Return on Assets | 3.96% |
| Revenue/Share (TTM) | $48.99 |
| Book Value | $39.34 |
| Price-to-Book | 7.91 |
| Price-to-Sales (TTM) | 6.71 |
| EV/Revenue | 6.08 |
| EV/EBITDA | 52.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 32.80% |
| Shares Outstanding | $102.15M |
| Float | $888.50M |
| % Insiders | 17.29% |
| % Institutions | 32.02% |
Analyst Ratings
Consensus ($408.24 target)
7
Strong Buy17
Buy1
HoldData last updated: 4/9/2026